Semma Therapeutics

Get Full Access

Description

  • Type 1 diabetes (T1D) is a chronic, life-threatening disease that affects millions of people worldwide. T1D is an autoimmune disease in which the patients immune system attacks and destroys pancreatic beta cells, which are responsible for regulating blood sugar levels by producing precise amounts of insulin. The discovery of injectable insulin in the 1920s changed T1D from a fatal disease to one that could be carefully managed through multiple daily blood glucose measurements and insulin injections. However, patients still face a lifetime of difficult disease management and serious complications including kidney failure, blindness and nerve damage. Nearly a century later, insulin injection remains the only treatment available to patients.Semma Therapeutics was founded to develop transformative therapies for patients who currently depend on insulin injections. Recent work led to the discovery of a method to generate billions of functional, insulin-producing beta cells in the laboratory. These cells develop in islet-like clusters grown from stem cells. Initial preclinical work in animal models of diabetes has shown that transplantation of these cells is sufficient to control blood glucose levels. This breakthrough technology has been exclusively licensed to Semma Therapeutics for the development of a cell-based therapy for diabetes. Ongoing research at Semma Therapeutics is focused on combining these proprietary cells with a state-of-the-art device that can protect these cells from the patients immune system and allow the beta cells to function as they do in non-diabetic individuals. Implantation of the beta cell-filled device has the potential to provide a true replacement for the missing beta cells in a diabetic patient and would not require patient immunosuppression. Semma Therapeutics is working to bring this new therapeutic option to the clinic and improve the lives of patients with diabetes.
  • location

    Headquarters:450 Kendall St , Cambridge, , United States

    More
  • Semma Therapeutics phone

    Phone Number:

  • Semma Therapeutics website

    Website: https://www.semma-tx.com

  • Semma Therapeutics employees

    Employees:25

  • Semma Therapeutics revenue

    Revenue:$10 - 50M

  • Semma Therapeutics legal name

    Legal Name:Semma Therapeutics

  • Semma Therapeutics's Social Media

    Semma Therapeutics linkedin Semma Therapeutics twitter
  • done Is this data correct?
  • |  NAICS Code: 541713  |

    Show More
Person level website identification

Group Chief Information Officer for Semma Therapeutics

Hasan Ozaslan

Group Chief Information Officer

Person level website visitor identification

Sell more in less time!

Buyer intent data, anonymous visitor identification, first party data integration backed by a massive contact database that will supercharge your sales team. Schedule a demo to learn more!

View Employees

Hasan Ozaslan

Group Chief Information Officer

Mandy Cromwell

Director

Tina Martinez

Operations Manager

Abeer Chaudhuri

Senior Laboratory And Procurement Manager

Frequently Asked Questions regarding Semma Therapeutics

  • Where are Semma Therapeutics's Headquarters?

    Semma Therapeutics's Headquarters are in 450 Kendall St ,Cambridge,,United States

  • What is Semma Therapeutics's official website?

    Semma Therapeutics's official website is https://www.semma-tx.com

  • What is Semma Therapeutics's Revenue?

    Semma Therapeutics's revenue is $10 - 50M

  • What is Semma Therapeutics's NAICS code?

    Semma Therapeutics's NAICS code is 541713

  • How many employees are working in Semma Therapeutics

    Semma Therapeutics has 25 employees

  • What is Semma Therapeutics's Industry?

    Semma Therapeutics is in the industry of Biotechnology

  • Who is Semma Therapeutics's Group Chief Information Officer?

    Semma Therapeutics's Group Chief Information Officer is Hasan Ozaslan

  • Who is Semma Therapeutics's Director?

    Semma Therapeutics's Director is Mandy Cromwell

Company Directory